BTK and autoimmune thrombocytopenic purpura: Pooled analysis from four publications (n = 574) showed no significant difference in the grade ≥3 AEs incidence between adult ITP patients who were given SYK and/or BTK inhibitors and those who were given placebo (RR 0.77; 95%CI: 0.52 – 1.14, p=0.19, I2 = 12%, random-effect model) (Figure 3B) (Table 3).